<DOC>
	<DOCNO>NCT02251769</DOCNO>
	<brief_summary>To determine effect single-dose steady-state Tipranavir/Ritonavir ( TPV/r ) 500 mg/200 mg bid steady-state pharmacokinetics clarithromycin determine effect standard high-fat test meal steady-state pharmacokinetics tipranavir .</brief_summary>
	<brief_title>Effects Single-dose Steady-state TPV/r Steady-state Pharmacokinetics Clarithromycin Preliminary Assessment Effects Standard High-fat Test Meal Steady-state Pharmacokinetics Tipranavir</brief_title>
	<detailed_description />
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Clarithromycin</mesh_term>
	<mesh_term>Tipranavir</mesh_term>
	<criteria>Male female subject 18 60 year age inclusive A Body Mass Index ( BMI ) 18 29 kg/m2 Signed informed consent prior trial participation Ability swallow multiple capsule without difficulty Ability ingest standard highfat test meal Acceptable laboratory value indicate adequate baseline organ function require time screen . Laboratory value consider acceptable severity less equal Grade 1 , base AIDS Clinical Trials Group ( ACTG ) Grading Scale Acceptable medical history , physical examination 12lead ECG require prior enter treatment phase study Willingness abstain alcohol 48 hour prior study Day 0 abstain alcohol duration study . In addition , ingestion red wine allow within 5 day prior Day 0 ( Visit 2 ) Willingness abstain grapefruit grapefruit juice product contain grapefruit juice start 10 day prior administration study drug end study Willingness abstain ingestion Seville orange , garlic supplement , St. John 's Wort , Milk Thistle , within 5 day treatment duration study Willingness abstain methylxanthinecontaining drink food ( coffee , tea , cola , energy drink , chocolate , etc . ) within 48 hour pharmacokinetic sample day last sample intensive sampling day collect Willingness abstain counter herbal medication duration study Willingness abstain vigorous physical exercise intensive pharmacokinetic day Reasonable probability completion study Nonsmokers least 3 month prior Day 0 Female subject reproductive potential : 1 . Have positive serum Î²hCG Visit 1 , Day 0 2 . Are use barrier contraceptive method least 3 month prior Visit 2 ( Day 0 ) 3 . Are willing use reliable method barrier contraception ( diaphragm condom ) , trial 30 day trial completion/termination 4 . Are breastfeed Use pharmacological contraceptive ( include oral , patch injectable contraceptive ) within 1 month prior study initiation duration study Use hormone replacement therapy within 1 month prior study initiation duration study Participation another trial investigational medicine within 60 day prior Day 0 ( Visit 2 ) Use prohibit medication list protocol within 30 day prior Day 0 ( Visit 2 ) Administration antibiotic within 10 day prior Day 0 ( Visit 2 ) trial History acute illness within 60 day trial initiation . Subjects exclude disorder great 60 day , opinion investigator , subject qualify healthy volunteer Serological evidence hepatitis B ( HBV ) hepatitis C ( HCV ) Serological evidence exposure HIV Recent history alcohol substance abuse ( within 6 month study period ) Blood plasma donation within 30 day prior Day 0 ( Visit 2 ) trial Subjects seat systolic blood pressure either &lt; 100 mm Hg &gt; 150 mm Hg Subjects history illness allergy , opinion investigator , might confound result study pose additional risk administer tipranavir ( TPV ) , ritonavir ( RTV ) clarithromycin ( CLR ) subject Subjects take , within 7 day prior Day 0 ( Visit 2 ) , overthecounter prescription drug , opinion investigator consultation BI clinical monitor , might interfere either absorption , distribution metabolism test substance Known hypersensitivity TPV , RTV , sulfonamide , CLR Lactose intolerance intolerance highfat food Allergies intolerance food soybean , wheat , milk , egg gluten Inability adhere requirement protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>